Biotoxtech Co. Ltd Market Cap ($21.51 Million)
Market Cap & Net Worth: Biotoxtech Co. Ltd (086040)
Biotoxtech Co. Ltd market cap. Biotoxtech Co. Ltd (KQ:086040) has a market capitalization of $21.51 Million (₩31.73 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24724 globally and #1786 in its home market, demonstrating a 4.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotoxtech Co. Ltd's stock price ₩2180.00 by its total outstanding shares 14556900 (14.56 Million). Also see 086040 cash flow metrics for how efficiently the company converts equity into cash flow.
Biotoxtech Co. Ltd Market Cap History (2015–2026)
Biotoxtech Co. Ltd market cap history from 2015 to 2026. Data shows change from $54.26 Million to $21.51 Million (-9.95% CAGR). Check today's stock price for Biotoxtech Co. Ltd for real-time trading data and today's change.
Index Memberships
Biotoxtech Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.01% | #937 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.01% | #937 of 1384 |
Weight: Biotoxtech Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biotoxtech Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotoxtech Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 086040 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Biotoxtech Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Biotoxtech Co. Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $55.74 Million | $22.26 Billion | $1.04 Billion | 0.00x | 0.05x |
| 2017 | $69.25 Million | $25.56 Billion | $1.39 Billion | 0.00x | 0.05x |
| 2018 | $81.98 Million | $27.25 Billion | $3.62 Billion | 0.00x | 0.02x |
| 2019 | $61.95 Million | $25.85 Billion | -$1.58 Billion | 0.00x | N/A |
| 2020 | $149.95 Million | $26.43 Billion | $2.61 Billion | 0.01x | 0.06x |
| 2021 | $79.12 Million | $32.72 Billion | $7.11 Billion | 0.00x | 0.01x |
| 2022 | $80.30 Million | $37.29 Billion | $2.73 Billion | 0.00x | 0.03x |
| 2023 | $60.77 Million | $32.63 Billion | -$4.88 Billion | 0.00x | N/A |
| 2024 | $32.90 Million | $41.34 Billion | -$6.43 Billion | 0.00x | N/A |
| 2025 | $27.77 Million | $47.02 Billion | $1.16 Billion | 0.00x | 0.02x |
Competitor Companies of 086040 by Market Capitalization
Companies near Biotoxtech Co. Ltd in the global market cap rankings as of November 5, 2026. Also see Biotoxtech Co. Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Biotoxtech Co. Ltd by market ranking:
- Peptron Inc (KQ:087010): Ranked #8741 globally with a market cap of $973.22 Million USD ( ₩1.44 Trillion KRW).
- Bioneer Corporation (KQ:064550): Ranked #19020 globally with a market cap of $100.18 Million USD ( ₩147.83 Billion KRW).
- MEDIPOST Co. Ltd (KQ:078160): Ranked #19385 globally with a market cap of $90.78 Million USD ( ₩133.96 Billion KRW).
- Cell Biotech Co. Ltd (KQ:049960): Ranked #20003 globally with a market cap of $77.90 Million USD ( ₩114.95 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8741 | Peptron Inc | KQ:087010 | $973.22 Million | ₩93700.00 |
| #19020 | Bioneer Corporation | KQ:064550 | $100.18 Million | ₩6690.00 |
| #19385 | MEDIPOST Co. Ltd | KQ:078160 | $90.78 Million | ₩8710.00 |
| #20003 | Cell Biotech Co. Ltd | KQ:049960 | $77.90 Million | ₩14890.00 |
Market Capitalization of Biotoxtech Co. Ltd (2015–2026)
Market capitalization of Biotoxtech Co. Ltd from 2015 to today. Between 2015 and today, Biotoxtech Co. Ltd's market cap moved from $54.26 Million to $ 21.51 Million, with a yearly change of -9.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩21.51 Million | -22.56% |
| 2025 | ₩27.77 Million | -15.59% |
| 2024 | ₩32.90 Million | -45.86% |
| 2023 | ₩60.77 Million | -24.32% |
| 2022 | ₩80.30 Million | +1.50% |
| 2021 | ₩79.12 Million | -47.24% |
| 2020 | ₩149.95 Million | +142.04% |
| 2019 | ₩61.95 Million | -24.43% |
| 2018 | ₩81.98 Million | +18.38% |
| 2017 | ₩69.25 Million | +24.25% |
| 2016 | ₩55.74 Million | +2.73% |
| 2015 | ₩54.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Biotoxtech Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.51 Million USD |
| MoneyControl | $21.51 Million USD |
| MarketWatch | $21.51 Million USD |
| marketcap.company | $21.51 Million USD |
| Reuters | $21.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotoxtech Co. Ltd
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and b… Read more